Kim, S., Dent, R., Im, S., Espié, M., Blau, S., Tan, A., … LOTUS, investigators. (2017). Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology, 18(10), 1360-1372. https://doi.org/10.1016/S1470-2045(17)30450-3